Entering text into the input field will update the search result below

Trevena stock rises after opioid pain drug Olinvyk shows promise in real-world studies

Mar. 30, 2023 7:44 AM ETTrevena, Inc. (TRVN) StockBy: Ravikash Bakolia, SA News Editor

Intravenous drip of medicine at the hospital.

NoonVirachada/iStock via Getty Images

Trevena (NASDAQ:TRVN) reported data from two real-world outcomes studies evaluating opioid pain drug Olinvyk (oliceridine).

VOLITION:

The study, dubbed VOLITION, enrolled 203 patients. Olinvyk-treated patients had a 52.2% gastrointestinal (GI) complete responder rate, defined as no vomiting and no antiemetic use in the

Recommended For You

More Trending News

About TRVN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
TRVN--
Trevena, Inc.